Kitazato

Kitazato EBIT Margin

The EBIT Margin (Operating Margin) of Kitazato (368A.T) as of Nov 17, 2026 is 56.13 %. In the previous year, EBIT Margin (Operating Margin) was 58.65 % — a change of -4.31% (lower).

EBIT Margin

56.13 %

YoY

-4.31%

Last updated:

EBIT Margin (Operating Margin) of Kitazato is 2025 56.13 % . EBIT Margin (Operating Margin) of Kitazato was 2024 58.65 % . It decreases by -4.31% lower compared to the previous year.

Kitazato's operating (EBIT) margin stands at 56.1%, up from 54.9% several years earlier.

The Kitazato EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2023
54.86 JPY
Jan 1, 2024
58.65 JPY
Jan 1, 2025
56.13 JPY
The Kitazato EBIT Margin history
YEAREBIT MarginYoY
56.13 %-4.31%
58.65 %+6.92%
54.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

EBIT Margin (Operating Margin) of Kitazato is 56.13 % in 2025.

EBIT Margin (Operating Margin) of Kitazato changed from 58.65 % to 56.13 %, representing a -4.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Kitazato since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Kitazato with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Kitazato

All Key Metrics — Kitazato